Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma

Journal of Allergy and Clinical Immunology

Volumn 128, Issue 2, 2011, Pages 315-322

  Bateman, Eric D ^a   Kornmann, Oliver ^b   Schmidt, Peter ^c   Pivovarova, Anna ^c   Engel, Michael ^c   Fabbri, Leonardo M ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b IKF Clinical Research Centre Respiratory Medicine   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

2 agonist receptor; airway obstruction; Arginine arginine genotype; bronchodilators; muscarinic receptor

Indexed keywords

ARGININE; BUDESONIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ALBUTEROL; ARGININE; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; PEAK EXPIRATORY FLOW RATE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 79960973276     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.06.004     Document Type: Article

References (36)

1. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3. Guidelines for the diagnosis and management of asthma, 2007. Bethesda: National Heart, Lung, and Blood Institute; 2007. Publication no. 07-4051.
2. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax 2008;63(suppl 4):iv1-121.
3. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
4. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Available at: http://www.ginasthma.org. Accessed 2009.
5. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, et al. POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
6. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006;533: 36-9. (Pubitemid 43340003)
7. Kapoor AS, Olsen SR, O'Hara C, Puttagunta L, Vethanayagam D. The efficacy of tiotropium as a steroid-sparing agent in severe asthma. Can Respir J 2009;16: 99-101.
8. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009;64:778-83.
9. Fardon T, Haggart K, Lee DK, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007;101:1218-28. (Pubitemid 46679499)
10. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008;102:50-6. (Pubitemid 350151827)
11. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26.
12. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, Gibbs M, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008;63:932-8. (Pubitemid 351832801)
13. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007;119:1337-48.
14. Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 2009;33:3-5.
15. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71.
16. Kazani S, Israel E. Long-acting beta-agonists and inhaled corticosteroids: is the whole greater than the sum of its parts? J Allergy Clin Immunol 2010;125:357-8.
17. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long-acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370: 2118-25. (Pubitemid 350296302)
18. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010;181:676-87.
19. Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14.
20. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;16(suppl):5-40.
22. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8. (Pubitemid 29411232)
23. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006;117:563-70. (Pubitemid 43340219)
24. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres J-L, Attali V. Maintaining asthma control in persistent asthma: Comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008;102:1124-31.
25. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med 2010;104:1110-20.
26. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003;111:57-65. (Pubitemid 36143292)
27. Ducharme FM, Chronin N, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010;(4): CD005533.
28. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium Handihaler in the treatment of COPD:a safety review. Int J Chron Obstruct PulmonDis 2009;4:397-409.
29. Bateman ED, Singh D, Smith D, Disse B, Towse L, Massey D, et al. Efficacy and safety of Tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010;5:197-208.
30. Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010;104:1460-72.
31. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-9.
32. Umeda N, Yoshikawa T, Kanazawa H, Hirata K, Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology 2008;13:346-52. (Pubitemid 351503141)
33. Bateman ED, Rennard SI, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009;22:533-42.
34. Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008;31:1379-80.
35. Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005;171:1096-102. (Pubitemid 40663720)
36. Bos ST, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007;30:653-61. (Pubitemid 351194824)